Caledonia Investments plc Logo Image

Caledonia Investments plc

Caledonia Investments plc Banner Image

Most Recent Annual Report

2017 Annual Report

Caledonia Investments plc

Caledonia Investments plc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About Caledonia Investments plc

51-200 Employees
Based in London, United Kingdom

Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure.

Ticker:
CLDN
Exchange:
LSE (See More LSE Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol